# Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

> **NCT03939975** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 50 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** pembrolizumab or nivolumab or JS001

## Key facts

- **NCT ID:** NCT03939975
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939975, "Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03939975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*